EVMN
Income statement / Annual
Last year (2025), Evommune Inc.'s total revenue was $13.00 M,
an increase of 85.71% from the previous year.
In 2025, Evommune Inc.'s net income was -$68.87 M.
See Evommune Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
| Operating Revenue |
$13.00 M |
$7.00 M |
$5.00 M |
| Cost of Revenue |
$0.00
|
$1.29 M
|
$1.00 M
|
| Gross Profit |
$13.00 M
|
$5.71 M
|
$4.00 M
|
| Gross Profit Ratio |
1
|
0.82
|
0.8
|
| Research and Development Expenses |
$74.04 M
|
$64.24 M
|
$32.00 M
|
| General & Administrative Expenses |
$20.03 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.03 M
|
$11.48 M
|
$9.85 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$94.07 M
|
$75.73 M
|
$41.85 M
|
| Cost And Expenses |
$94.07 M
|
$77.01 M
|
$42.85 M
|
| Interest Income |
$3.32 M
|
$3.24 M
|
$3.86 M
|
| Interest Expense |
$0.00
|
$34.00 K
|
$58.00 K
|
| Depreciation & Amortization |
$1.39 M
|
$1.29 M
|
$1.00 M
|
| EBITDA |
-$79.68 M |
-$65.49 M |
-$33.00 M |
| EBITDA Ratio |
-6.13
|
-9.36
|
-6.6
|
| Operating Income Ratio |
-6.24
|
-10
|
-7.57
|
| Total Other Income/Expenses Net |
$12.20 M
|
$3.20 M
|
$3.80 M
|
| Income Before Tax |
-$68.87 M
|
-$66.81 M
|
-$34.05 M
|
| Income Before Tax Ratio |
-5.3
|
-9.54
|
-6.81
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$68.87 M
|
-$66.81 M
|
-$34.05 M
|
| Net Income Ratio |
-5.3
|
-9.54
|
-6.81
|
| EPS |
-2.18 |
-2.27 |
-1.13 |
| EPS Diluted |
-2.18 |
-2.27 |
-1.13 |
| Weighted Average Shares Out |
$31.52 M
|
$30.08 M
|
$30.08 M
|
| Weighted Average Shares Out Diluted |
$31.52 M
|
$30.08 M
|
$30.08 M
|
| Link |
|
|
|
